FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft Versus Host Disease, Including A New Oral Suspension
Recommended
FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft Versus Host Disease, Including A New Oral Suspension
The FDA approved ibrutinib for pediatric patients ≥ 1 year of age with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->